Analysis of tumor markers in the cytological fluid obtained from computed tomography-guided needle aspiration biopsy for the diagnosis of non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 6, Issue 8, 2011, Pages 1330-1335

  Hong, Yoo Jin ^a   Hur, Jin ^a   Lee, Hye Jeong ^a   Nam, Ji Eun ^a   Kim, Young Jin ^a   Kim, Hua Sun ^a   Kim, Hee Yeong ^a   Kim, Se Kyu ^b   Chang, Joon ^b   Kim, Joo Hang ^b,c   Chung, Kyung Young ^b   Choi, Byoung Wook ^a   Choe, Kyu Ok ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

CEA; CT guided needle aspiration biopsy (NAB); CYFRA 21 1; Cytological fluid; SCC Ag; Tumor marker

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19; SQUAMOUS CELL CARCINOMA ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; BENIGN TUMOR; CANCER CYTODIAGNOSIS; CLINICAL TRIAL; COMPUTED TOMOGRAPHY GUIDED NEEDLE ASPIRATION BIOPSY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HUMAN; IMMUNORADIOMETRIC ASSAY; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

EID: 80051773986     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31822462b1     Document Type: Article

References (31)

1. Granville CA, Dennis PA. An overview of lung cancer genomics and proteomics. Am J Respir Cell Mol Biol 2005;32:169-176. (Pubitemid 40387642)
2. Sung HJ, Cho JY. Biomarkers for the lung cancer diagnosis and their advances in proteomics. BMB Rep 2008;41:615-625.
3. Mulshine JL, Sullivan DC. Lung cancer screening. N Engl J Med 2005;352:2714-2720. (Pubitemid 41007826)
4. Li H, Boiselle PM, Shepard JO, et al. Diagnostic accuracy and safety of CT-guided percutaneous needle aspiration biopsy of the lung: comparison of small and large pulmonary nodules. Am J Roentgenol 1996;167: 105-109. (Pubitemid 26196919)
5. Perlmutt LM, Johnston WW, Dunnick NR. Percutaneous transthoracic needle aspiration: a review. Am J Roentgenol 1989;152:451-455. (Pubitemid 19066375)
6. Quint LE, Kretschmer M, Chang A, et al. CT-guided thoracic core biopsies: value of a negative result. Cancer Imaging 2006;6:163-167.
7. Molina R, Filella X, Augé JM, et al. Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol 2003;24:209-218. (Pubitemid 37500571)
8. Bréchot JM, Chevret S, Nataf J, et al. Diagnostic and prognostic value of Cyfra 21-1 compared with other tumour markers in patients with non-small cell lung cancer: a prospective study of 116 patients. Eur J Cancer 1997;33:385-391. (Pubitemid 27168063)
9. Moertel CG, Fleming TR, Macdonald JS, et al. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 1993;270:943.
10. Seemann MD, Beinert T, Fürst H, et al. An evaluation of the tumour markers, carcinoembryonic antigen (CEA), cytokeratin marker (CYFRA 21-1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions. Lung Cancer 1999;26: 149-155. (Pubitemid 30114217)
11. Plebani M, Basso D, Navaglia F, et al. Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results? Br J Cancer 1995;72:170-173.
12. Niklinski J, Furman M, Chyczewska E, et al. Diagnostic and prognostic value of the new tumour marker CYFRA 21-1 in patients with squamous cell lung cancer. Eur Respir J 1995;8:291-294.
13. Tanoue LT, Detterbeck FC. New TNM classification for non-small-cell lung cancer. Expert Rev Anticancer Ther 2009;9:413-423.
14. Brambilla E, Travis WD, Colby TV, et al. The new World Health Organization classification of lung tumours. Eur Respir J 2001;18: 1059-1068. (Pubitemid 34092881)
15. Kothary N, Lock L, Sze DY, et al. Computed tomography-guided percutaneous needle biopsy of pulmonary nodules: impact of nodule size on diagnostic accuracy. Clin Lung Cancer 2009;10:360-363.
16. Larscheid RC, Thorpe PE, Scott WJ. Percutaneous transthoracic needle aspiration biopsy: a comprehensive review of its current role in the diagnosis and treatment of lung tumors. Chest 1998;114:704-709. (Pubitemid 28433728)
17. Colquhoun SD, Rosenthal DL, Morton DL. Role of percutaneous fineneedle aspiration biopsy in suspected intrathoracic malignancy. Ann Thorac Surg 1991;51:390-393.
18. Patz EF Jr, Fidler J, Knelson M, et al. Significance of percutaneous needle biopsy in patients with multiple pulmonary nodules and a single known primary malignancy. Chest 1995;107:601-604.
19. Mitruka S, Landreneau RJ, Mack MJ, et al. Diagnosing the indeterminate pulmonary nodule: percutaneous biopsy versus thoracoscopy. Surgery 1995;118:676-684.
20. Kim MJ, Lee JS, Do KH, et al. Percutaneous fine needle aspiration biopsy for the intrathoracic lesions: what is the meaning of nondiagnostic results? J Korean Radiol Soc 2003;48:401-405.
21. Cho WC, Yip TT, Yip C, et al. Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin Cancer Res 2004;10:43-52. (Pubitemid 38114160)
22. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002;1:845-867.
23. Hanash SM, Pitteri SJ, Faca VM. Mining the plasma proteome for cancer biomarkers. Nature 2008;452:571-579. (Pubitemid 351483371)
24. Cho JY, Sung HJ. Proteomic approaches in lung cancer biomarker development. Expert Rev Proteomics 2009;6:27-42.
25. Molina R, Agusti C, Mane JM, et al. CYFRA 21-1 in lung cancer: comparison with CEA, CA 125, SCC and NSE serum levels. Int J Biol Markers 1994;9:96-101. (Pubitemid 24225520)
26. Wieskopf B, Demangeat C, Purohit A, et al. Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role. Chest 1995;108:163-169.
27. Barlési F, Gimenez C, Torre JP, et al. Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer. Respir Med 2004;98:357-362. (Pubitemid 38443696)
28. Ferrer J, Villarino MA, Encabo G, et al. Diagnostic utility of CYFRA 21-1, carcinoembryonic antigen, CA 125, neuron specific enolase, and squamous cell antigen level determinations in the serum and pleural fluid of patients with pleural effusions. Cancer 1999;86:1488-1495. (Pubitemid 29489782)
29. Lucidarme O, Howarth N, Finet JF, et al. Intrapulmonary lesions: percutaneous automated biopsy with a detachable, 18-gauge, coaxial cutting needle. Radiology 1998;207:759-765. (Pubitemid 28279910)
30. Moore EH. Technical aspects of needle aspiration lung biopsy: a personal perspective. Radiology 1998;208:303-318. (Pubitemid 28373731)
31. Flower CD, Verney GI. Percutaneous needle biopsy of thoracic lesions: an evaluation of 300 biopsies. Clin Radiol 1979;30:215-218. (Pubitemid 9138034)